Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

Официальное название

Neoadjuvant ADT +/- Darolutamide Followed by Radical Prostatectomy for High-risk Prostate Cancer: a Randomized, Open Label Trial

Обзор

The purpose of this study is to determine if treatment with Darolutamide plus androgen deprivation therapy (ADT) before radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and pathological tumor volume with minimal residual disease (MRD)) as compared to ADT.

Вмешательства

• Препарат Darolutamide
  600 mg orally twice daily for 12 weeks before radical prostatectomy
• Препарат Goserelin 3.6 mg
  3.6 mg goserelin hypodermic once per 4 weeks

Первичные конечные точки

• Pathologic Complete Response Rate [Срок оценки: After 12 weeks of neoadjuvant therapy + RP + PLND]
• Proportion of Subjects With Minimal Residual Disease [Срок оценки: After 12 weeks of neoadjuvant therapy + RP + PLND]

Вторичные конечные точки (8)

• Rate of Stage Degradation [Срок оценки: After 12 weeks of neoadjuvant therapy + RP + PLND]
• Rate of Positive Surgical Margins [Срок оценки: After 12 weeks of neoadjuvant therapy + RP + PLND]
• Rate of Complete Serum Remission [Срок оценки: After 12 weeks of neoadjuvant therapy]
• Proportion of subjects without PSA progression [Срок оценки: 2 years after RP]
• Imaging Response Rate [Срок оценки: After 12 weeks of neoadjuvant therapy]
• Recovery time of urinary continence (day) [Срок оценки: 1 years after RP]
• biochemical recurrence-free survival (bRFS) [Срок оценки: 3 years after RP]
• metastasis-free survival (MFS) [Срок оценки: 5 years after RP]

Критерии участия

Критерии включения

• Patients must be ≥ 18 and ≤75 years of age.
• All patients must have a histologically or cytologically diagnosis of prostate cancer and must be eligible for radical prostatectomy.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score ≤1.
• All patients must complete mpMRI or 68Ga-PSMA PET / CT before and after neoadjuvant treatment.
• All patients must undergo thorough tumor staging and meet one of the following criteria: 1. multi-parameter MRI or PSMA PET / CT shows clinical staging of primary tumor ≥ cT2c or cN+or locally advanced, 2. Gleason score of primary tumor ≥ 8, 3. prostate specific antigen (PSA) ≥20 ng/ml.
• Patients must have adequate organ function as defined by the following criteria(within 28 days prior to registration):

white blood cell (WBC) ≥ 4.0 × 109 / L platelets≥ 100 × 109 / L hemoglobin ≥ 9 g / dL international normalized ratio (INR) < 1.5. total bilirubin (TBIL)≤1.5 x upper limit of normal (ULN) SGOT (AST) and SGPT (ALT) ≤ 2.5 x ULN serum creatinine ≤2×ULN

• Patients must participate voluntarily and sign an informed consent form (ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must be willing to obey the prohibitions and restrictions specified in the research protocol.

Критерии исключения

• clinical or radiological evidence of regional or extra-regional lymph node metastases or bone metastases or visceral metastases.
• Prior androgen deprivation therapy (medical or surgical) or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy.
• severe or uncontrolled concurrent infections.
• New York Heart Association Class III or IV congestive heart failure at the time of screening.
• uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection.
• Patients with mental illness, mental disability or inability to give informed consent are not eligible.
• Patients have had other malignancies other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• The First Affillated Hospital, the Air Force Medical University — Xi’an

Идентификаторы

NCT: NCT06575257 · KY20242118-C-1

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗